H.C. Wainwright raised the firm’s price target on Harrow (HROW) to $69 from $64 and keeps a Buy rating on the shares. The company reported a “robust” Q3 and its growth momentum for Vevye and Iheezo should continue in 2026, the analyst tells investors in a research note. The firm also believes Harrow’s new product launches in 2026 should further drive sales growth.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow Health Reports Strong Q3 2025 Results
- Cantor Fitzgerald reiterates Overweight rating on Harrow, ups target to $94
- Harrow price target raised to $94 from $76 at Cantor Fitzgerald
- Harrow Health: Strong Product Performance and Strategic Moves Justify Buy Rating
- Closing Bell Movers: CoreWeave down over 5% on lower sales, higher capex view